Clinical Trial News

ProJenX, Inc. forms Clinical Advisory Board (ClAB) with experts in ALS and neurodegenerative diseases to guide clinical development of prosetin, a novel brain-penetrant MAP4K inhibitor. Prosetin is being evaluated in Study PRO-101, a Phase 1 trial assessing safety and tolerability in healthy volunteers and ALS participants, with positive early results.

VTP-1000, an investigational immunotherapy, aims to help the immune system tolerate gluten in the AVALON celiac disease clinical trial. The phase 1 trial assesses VTP-1000's safety and tolerability in adults with celiac disease on a gluten-free diet. Potential participants must be 18-65 years old, diagnosed with celiac disease within the past 10 years, and live in the US. The study, conducted across several US locations, offers compensation for time and travel. Learn more at avalon.celiac.org.

Professor Fatima Merchant leads a team developing patient-specific molds for breast cancer patients, funded by a $2.7 million NIH grant. The project aims to improve reconstruction efficiency and psychosocial adjustment, featuring a randomized controlled clinical trial to evaluate impact.

A double-blind, randomized, controlled trial found limited impact of cannabidiol on health-related quality of life for people with long-term controlled HIV.

AiViva Biopharma completed enrollment and dosing in a phase 1 trial of AIV007, a tyrosine kinase inhibitor for wet AMD and DME, administered via periocular injection. The trial, involving 18 participants, aims to evaluate safety over 6 months, with full results expected in Q1 2025.

Novo Nordisk registered a new clinical study to examine long-term effects of semaglutide on teens. Semaglutide, in drugs Ozempic and Wegovy, mimics a hormone regulating blood sugar and suppressing appetite. FDA approved Wegovy for teens in 2022, though some doctors are cautious due to lack of long-term data. The trial will monitor 500 teens over three years for weight loss maintenance and adverse effects.

JW Therapeutics' relma-cel (Carteyva) received NMPA approval for r/r MCL, becoming the first CAR-T therapy for this indication in China. The approval was based on a pivotal trial showing 81.36% best objective response rate and 67.80% best complete response rate among 59 evaluable patients. Relma-cel is also approved for r/r LBCL and FL, and is being explored for autoimmune diseases and SLE.

Cedars-Sinai Medical Center in LA added to Edelife Clinical Trial for XLHED, offering prenatal treatment for boys affected by x-linked hypohidrotic ectodermal dysplasia. This marks the second US location, aiming for 15-20 participants, with the trial also available in Europe. Led by Dr. Ophir Klein, the trial seeks to confirm the safety and efficacy of ER-004, a potential first-of-its-kind medicine for structural birth defects, with all associated expenses covered for participating families.

The Jablons' lab has advanced novel pan RAS and dual anti-PARP/anti-microtubule inhibitors in clinical trials, and is conducting an international trial for an early-stage lung cancer diagnostic assay. Ongoing basic research focuses on developmental pathways like WNT and Hippo signaling, with immuno-therapeutic approaches targeting these pathways. A 14 gene molecular assay for early-stage non-small cell lung cancer predicts prognosis and guides adjuvant therapy, saving thousands of patients. The lab also demonstrated aberrant Wnt signaling causing lung cancer and mesothelioma, developing an anti-Wnt2-ADC showing significant anti-tumor effects, with a Phase I trial upcoming.

A new clinical trial at the University of Calgary uses probenecid, a gout drug, to help with opioid withdrawal symptoms, based on research showing it reduces withdrawal in rodents by disrupting abnormal brain-spinal cord communication during withdrawal.